Robert L. Coleman, MD, FACOG, FACS

Comprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.

Expert oncologists review the current PARP inhibitor treatment indications for patients with advanced ovarian cancer and discuss how to best manage patients who have been impacted by the recent updates to the PARP inhibitors.

Drs Coleman and Monk discuss what led to the recent withdrawal of several indications for PARP inhibitors in the treatment of advanced ovarian cancer.

Expert oncologists give an overview of PARP inhibitors available for the treatment of patients with advanced ovarian cancer and review adverse events seen with each agent.

Experts on advanced ovarian cancer give detailed insights on the role of biomarker testing and identify important biomarkers.

Robert L Coleman, MD, FACOG, FACS, and Bradley J Monk, MD, FACOG, FACS, provide an overview of advanced ovarian cancer and discuss its prevalence and diagnosis process.

Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.

The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.

Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.

A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.

Drs Coleman and Westin continue the discussion of antibody-drug conjugates for treatment of ovarian cancer.

Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.

Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.

Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.

A look at the maintenance treatment strategies for advanced or metastatic ovarian cancer.

Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.

Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.

Dr Michael Birrer reviews data from the PAOLA-1 trial investigating bevacizumab combination therapy for frontline maintenance therapy in advanced ovarian cancer.

Bradley J. Monk, MD, FACOG, FACS, generates a discussion on the use of PARP inhibitors in ovarian cancer treatment.

Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.

Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.

Robert L. Coleman, MD, FACOG, FACS, discusses the potential of tisotumab vedotin in cervical cancer.

Robert L. Coleman, MD, FACOG, FACS, discusses the potential to move immunotherapy into earlier lines of treatment in cervical cancer.

Robert L. Coleman, MD, FACOG, FACS, discusses the clinical implications of the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 trial in women with previously treated recurrent or metastatic cervical cancer.

Robert L. Coleman, MD, FACOG, FACS, discusses recent advances made in the treatment of patients with ovarian cancer and remaining questions regarding the role of immunotherapy.

Robert L. Coleman, MD, FACOG, FACS, discusses recent advancements made in the cervical cancer space.

Robert L. Coleman, MD, FACOG, FACS, discusses the results of the phase III VELIA trial examining veliparib in combination with chemotherapy in ovarian cancer.

Robert L. Coleman, MD, FACOG, FACS, discusses the impact of the VELIA trial on ovarian cancer practice.

Robert L. Coleman, MD, FACOG, FACS, discusses the safety profile of veliparib examined in the VELIA trial looking at patients with high-grade serous ovarian cancer.

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the use of veliparib in ovarian cancer.